Patients with the SCN1A demonstrated better response to PER compared to other sodium channelopathies (including SCN2A and SCN8A). Clinical features, such as the age of seizure onset and developmental delays, had no statistical significance. This evidence concerns the gene SCN1A and Global developmental delay.